2nd Annual
Canadian Glaucoma Meeting

Program

April 8–10, 2016
The Fairmont Banff Springs Hotel

Canadian Glaucoma Society
Société Canadienne de Glaucome
Dear Colleagues

Welcome to Banff, Alberta, and your second annual Canadian Glaucoma Meeting!

This really is your meeting as a Canadian Glaucoma Society Member. It is your input and involvement that will make the meeting successful.

The ongoing efforts of Hady Saheb and his CGM Team of Ike Ahmed, Paul Harasymowycz, Steve Schendel and our meeting planner Kelly Forgala are indispensable.

I would like to thank our valued sponsors Alcon and Allergan (Gold sponsors), iMedPharma, Bausch & Lomb, Glaukos, Salient Medical Solutions, (Bronze), Labitician Ophthalmics (Friend). Please visit with them during the program breaks.

We hope you will enjoy an informative and fun weekend with our Canadian glaucoma family.

Thank you for attending, and think snow!

Jamie Taylor
President
Canadian Glaucoma Society
Dear Colleagues

Welcome to the Canadian Glaucoma Society Meeting!

As a Canadian Glaucoma Society member, this is your meeting!

We hope to provide a unique meeting emphasizing professional and social interaction with colleagues across the country. In a more focused way than other national meetings, we are aiming the content at clinically relevant topics for the glaucoma subspecialist.

We hope the format and size of the CGM will launch discussions and insights that we can apply when we return to our practices. We also hope you and any family members attending will have fond social memories from beautiful Banff to take back with you.

We are fortunate in having broad corporate sponsorship in the form of unrestricted educational grants and wish to thank all our sponsors.

Looking forward to your participation and feedback on how to make the next CGM even better!

Hady Saheb MD MPH (Chair)
Ike Ahmed MD
Paul Harasymowycz MD MSc
Steven Schandel MD
Your CGM Planning Committee
Exhibit Floor Plan

1. Salient Medical Solutions
2. iMed Pharma
3. Allergan
4. Glaukos
5. Bausch & Lomb
6. Alcon
KEYNOTE

Steven L. Mansberger, MD, MPH is an Senior Scientist and Director of fellowship and glaucoma services for Devers Eye Institute in Portland, Oregon. He also holds appointments at Oregon Health Science University (OHSU) as Affiliate Professor of Ophthalmology and Adjunct Associate Professor in Public Health and Preventive Medicine.

Dr. Mansberger completed his medical degree from Indiana University School of Medicine, an ophthalmology residency at Shiley Eye Center at the University of California, San Diego, and a glaucoma fellowship at Devers Eye Institute. He also earned a Masters in Public Health degree (MPH-Biostatistics/Epidemiology) from OHSU.

Dr. Mansberger has had research grant support as principal investigator from the National Eye Institute, Center for Disease Control and Prevention, and the American Glaucoma Society. He has won numerous awards including “Best Doctors in America”, Heed Fellowship, The Robert Watske Ophthalmology Instructor of the Year, American Glaucoma Society Clinician-Scientist award, among others. He is on the Editorial Board for Journal of Glaucoma and American Journal of Ophthalmology, and the Executive Editor for epidemiology for the American Journal of Ophthalmology. He is an invited reviewer for JAMA Ophthalmology, British Journal of Ophthalmology, Ophthalmology, Investigative Ophthalmology and Visual Science, Survey of Ophthalmology, as well as 8 other journals. He has authored over 200 journal articles, book chapters, and abstracts.

LEARNING OBJECTIVES

The overall event-learning objective is to develop the knowledge and understanding of professional behaviours and values. The information shared will contribute to the improvement of patient care.

Measurable learning objectives:
1. Describe current availability, funding barriers, and potential solutions of MIGS in Canada,
2. Compare current concepts of target pressure to that discussed in Canadian glaucoma guidelines,
3. Recognize impact of chronic use of glaucoma medications on the outcome of future glaucoma surgery,
4. Discuss potential novel surgical products that may impact the glaucoma treatment algorithm,
5. Interpret the impact of unmet surgical glaucoma needs,
6. Compare different treatment options for uncontrolled glaucoma in elderly patients

Accreditation Statement
This meeting is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. This meeting was approved by the Canadian Ophthalmological Society. Physicians may claim a maximum of 7.75 hours.

Wifi information.
Network: Fairmont Meetings
code: glaucoma
FRIDAY, APRIL 8, 2016
3:00 PM–6:00 PM • PRE-REGISTRATION
6:00 PM–9:00 PM • WELCOME RECEPTION
Mt. Stephan Hall

SATURDAY, APRIL 9, 2016
All CGM programming takes place in the Alberta and New Brunswick Rooms
7:00 AM–8:00 AM • REGISTRATION
7:00 AM–7:45 AM • BREAKFAST
Moderator: Hady Saheb
8:00 AM–8:10 AM • WELCOME REMARKS
8:10 AM–9:00 AM • DR. STEVEN MANSBERGER KEYNOTE ADDRESS
“How to know if you are losing the battle of Glaucoma”

LEARNING OBJECTIVES:
1 Detect functional progression
2 Identify the limitations of detecting structural progression

9:00 AM–10:00 AM • MEDICAL UPDATE PART 1
Update on Target Pressure (Karim Damji)
Glaucoma Medications and their effect on conjunctiva and future surgery (Catherine Birt)

LEARNING OBJECTIVES:
1 Compare current concept of target pressure to that discussed in Canadian glaucoma guidelines
2 Recognize the impact of chronic use of glaucoma medications on the outcome of future glaucoma surgery
3 Discuss novel products that may impact the glaucoma treatment algorithm
10:00 AM–10:30 AM • HEALTH BREAK

10:30 AM–11:15 AM • MEDICAL UPDATE PART 2
Medical Splash: What’s Making a Comeback
What’s New and What’s in the Pipeline?
Vesneo (Kulbir Gill)
Rho-kinase Inhibitors, (Mohammad Hamid)
SR Glaucoma Meds (Byrce Ford)
Ganglion Cell Analysis (Paul Mackenzie)
Micro Pulse (Matthew Schlenker)
Octopus VF (Lisa Heckler)
Casia Tomey Anterior Segment (Nawaf Almarzouki)

LEARNING OBJECTIVES:
1 Compare current concept of target pressure to that discussed in Canadian glaucoma guidelines
2 Recognize the impact of chronic use of glaucoma medications on the outcome of future glaucoma surgery
3 Discuss novel products that may impact the glaucoma treatment algorithm

11:15 AM–12:15 PM • MIGS FUNDING IN CANADA—CURRENT AFFAIRS
Availability of MIGS in Canada (Cindy Hutnik)
Panel: What is the future of glaucoma surgical device funding in Canada? (Bryce Ford, Paul Harasymowycz, Cindy Hutnik. Moderator: Hady Saheb)

LEARNING OBJECTIVES:
1 Describe the current availability of MIGS in Canada
2 Compare barriers to MIGS funding throughout Canada
3 Propose solutions for future funding of MIGS
12:15 PM–1:15 PM • LUNCH
12:45 PM–1:15 PM • CGM BUSINESS MEETING
(Over Lunch)

6:30 PM–10:00 PM • CGM RECEPTION & DINNER
Cascade Ballroom
AGENDA

SUNDAY, APRIL 10, 2016
All CGM programming takes place in the Alberta and New Brunswick Rooms

7:00 AM–8:00 AM • BREAKFAST
Moderator: Steven Schendel

8:00 AM–9:00 AM • LASER UPDATE
Cyclodestruction: What are Today’s Options?
(Steven Schendel)

Case Controversy 2.0: PAC: Occludable angles and high IOP following LPI:
Medication (Marcelo Nicolela)
Iridoplasty (Delan Jinapriya)
Lens extraction (Ali Hafez)

LEARNING OBJECTIVES:
1. Compare various modalities of treatment for angle closure
2. Describe current options for cyclodestrucive procedures

9:00 AM–10:05 AM • GLAUCOMA SURGERY PT 1
Surgery Splash: What’s new?
CLASS (Baseer Khan)
G2 iStent (Andrew Toren)
GATT (Patrick Gooi)
Cross-linking in bleb leaks (Qianqian Wang)
Xen: The West Coast Experience (Priya Gupta)
Expanding indications for primary tubes (Younes Agoumi)

LEARNING OBJECTIVES:
1. Discuss novel surgical products that may impact the glaucoma treatment algorithm
2. Interpret the impact of unmet surgical glaucoma needs
3. Compare different treatment options for uncontrolled glaucoma in elderly patients

10:05 AM–10:35 AM • HEALTH BREAK
Moderator: Delan Jinapriya

10:30 AM–11:10 AM • DR. STEVEN MANSBERGER KEYNOTE ADDRESS
“Unmet Needs of Current Glaucoma Surgery”

LEARNING OBJECTIVES:
1. Predict results of new surgeries and incorporate findings into current regimen
2. Recognize the limitations of current surgeries, and future needs

11:10 AM–11:40 AM • GLAUCOMA SURGERY PT 2
Case Controversy 2.0: Healthy 92-year old female patient with IOP of 31 and advanced glaucoma (MD -14dB); contralateral eye stable status post remote trab with MD -16.
Observation (Garfield Miller)
Angle Surgery (Michael Dorey)
Trab (Enitan Sogbesan)
Tube (Andrew Crichton)

LEARNING OBJECTIVES:
1. Discuss novel surgical products that may impact the glaucoma treatment algorithm
2. Interpret the impact of unmet surgical glaucoma needs
3. Compare different treatment options for uncontrolled glaucoma in elderly patients

11:40 AM–12:15 PM • SURGICAL VIDEOS
Resident Surgical Teaching (Marjorie Carbonneau)
Making a unicameral eye: IZHV (Toby Chan)
Make the Ahmed valveless (Paul Mackenzie)
The glaucoma’s surgeon’s mission to flatten RPE folds (Garfield Miller)

LEARNING OBJECTIVES:
1. Discuss novel surgical products that may impact the glaucoma treatment algorithm
2. Interpret the impact of unmet surgical glaucoma needs
3. Compare different treatment options for uncontrolled glaucoma in elderly patients

12:15 PM–12:20 PM • CLOSING REMARKS

12:20 PM–1:20 PM • LUNCH (To-Go Options)

Wifi information.
Network: Fairmont Meetings code: glaucoma
CGS BUSINESS MEETING AGENDA

SATURDAY, APRIL 9TH
12:45 PM–1:15 PM
Alberta Room

CGS Incorporation Update

COS Offer of Position on COS Board of Directors for CGS Executive

CGS Committees, Current Members, Volunteer Opportunities

Research Proposal on PXF and Cataract Surgery—Karim Damji, Marcelo Nicolela

CGM Updates, by any other name—Hady Saheb

MIGS actions, OD therapeutics, etc.

GRSC Update

New Business


Alcon Canada

is the global leader in eye care, providing innovative products that enhance quality of life by helping people see better.

This includes the full range of ophthalmic surgical supplies, instrumentation, and pharmaceuticals together with dry eye and contact lens care solutions.
About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model—Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

À propos d’Allergan

Allergan plc (NYSE : AGN), dont le siège social est situé à Dublin, en Irlande, est une société pharmaceutique mondiale unique en son genre, chef de file d'un nouveau modèle au sein de l'industrie, celui des entreprises pharmaceutiques axées sur la croissance. Allergan se consacre à la mise au point, à la fabrication et à la commercialisation de produits pharmaceutiques de marque innovants, de médicaments génériques et en vente libre ainsi que de produits biologiques de grande qualité pour les patients du monde entier.

Allergan commercialise un portefeuille de produits qui sont les meilleurs de leur catégorie et constituent de précieux traitements dans les domaines des affections du système nerveux central, des soins oculaires, de la médecine esthétique, de la gastro-entérologie, de la santé des femmes, de l'urologie, des maladies cardiovasculaires et des traitements anti-infectieux, et l'entreprise occupe le troisième rang mondial dans le secteur des génériques, ce qui lui permet d'offrir aux patients du monde entier un meilleur accès à des médicaments de grande qualité à prix abordable. La société Allergan est un chef de file de la recherche et du développement dans l’industrie pharmaceutique, où elle détient l’un des plus importants pipelines de produits en cours de mise au point et est en tête des demandes d’homologation de produits génériques à l’échelle mondiale.

Allergan, qui mène ses activités commerciales dans une centaine de pays, s’engage à collaborer avec les médecins, les professionnels de la santé et les patients pour fournir des traitements utiles et innovants qui aident les personnes du monde entier à vivre plus longtemps et en meilleure santé.

Pour de plus amples renseignements, consultez le site Web d’Allergan à l’adresse www.allergan.com.
Each day, we have 14 billion little reminders to continue advancing eye health.

From the moment we open our eyes and start to view the possibilities of each new day, we look at how we can improve the well-being of the world’s 14 billion eyes.

We’re Bausch + Lomb, a company solely focused on advancing the vision and care of the world’s eyes.
Banff Sunset

Canadian Glaucoma Society

Proudly Presents the First Annual Canadian Glaucoma Meeting